SCHEMBL1129340

SCHEMBL1129340

CC1(C)OB(c2ccc(C(=O)c3ccccc3)c(Cl)c2)OC1(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 1/20 0.49
LIPG Q9Y5X9 3/20 0.45
LPL P06858 2/20 0.45
MAPK13 O15264 1/20 0.42
MAPK12 P53778 1/20 0.42
MAPK11 Q15759 1/20 0.42
MAPK14 Q16539 1/20 0.42
SRD5A2 P31213 1/20 0.41
TP53 P04637 1/20 0.39
RXRA P19793 1/20 0.39
ROCK1 Q13464 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
AAK1 Q2M2I8 1/20 0.39
KDM4E B2RXH2 2/20 0.38
CYP1A2 P05177 2/20 0.38
HPGD P15428 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP3A4 P08684 1/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1131421 0.84 TSHR (0.47) P4HBLIPGLPLTP53ROCK1
SCHEMBL1129235 0.84 ROCK1 (0.49) P4HBLIPGLPLSRD5A2RXRA
SCHEMBL25981423 0.83 KMT2A (0.52) P4HBLIPGLPLKMT2AF2
SCHEMBL2932908 0.82 P4HB (0.50) P4HBLIPGLPLRXRAROCK1
SCHEMBL1128778 0.82 MAPT (0.48) P4HBLIPGLPLRXRAMAPT
SCHEMBL27176410 0.81 AAK1 (0.42) P4HBLIPGLPLROCK1AAK1
SCHEMBL31255376 0.81 RXRA (0.42) P4HBLIPGLPLMAPK13MAPK12
SCHEMBL15288517 0.81 AAK1 (0.42) P4HBLIPGLPLROCK1MAPT
SCHEMBL1329917 0.80 KMT2A (0.45) P4HBLIPGLPLROCK1AAK1
SCHEMBL1129173 0.80 ALDH1A1 (0.52) P4HBLIPGLPLMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
EP-2283020-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI Pharmaceuticals, Inc. (US) 2011-02-16 EP disclosed
WO-2009143051-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-26 WO disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 P4HB 882/4885LIPG 4744/4885LPL 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.